Literature DB >> 28078106

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Ghassan K Abou-Alfa1, Jesper B Andersen2, William Chapman3, Michael Choti4, Stuart J Forbes5, Gregory J Gores6, Theodore S Hong7, James J Harding1, Matthew G Vander Heiden8, Milind Javle9, Robin K Kelley10, Lawrence N Kwong8, Maeve Lowery1, Allyson Merrell11, Katsuyuki Miyabe6, Andrew Rhim12, Supriya Saha13, Daniela Sia14, Suebpong Tanasanvimon15, Alan Venook10, Juan W Valle16, Chad Walesky17, Jonathan Whetstine7, Holger Willenbring10, Andrew X Zhu7, Donna Mayer18, Ben Z Stanger11.   

Abstract

Entities:  

Year:  2016        PMID： 28078106      PMCID： PMC5177567          DOI： 10.21037/jgo.2016.11.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  34 in total

1.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

2.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 3.  Roles of liver fluke infection as risk factor for cholangiocarcinoma.

Authors:  Paiboon Sithithaworn; Puangrat Yongvanit; Kunyarat Duenngai; Nadda Kiatsopit; Chawalit Pairojkul
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-10       Impact factor: 7.027

4.  Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

Authors:  J W Valle; J Furuse; M Jitlal; S Beare; N Mizuno; H Wasan; J Bridgewater; T Okusaka
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

5.  Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.

Authors:  Sayaka Sekiya; Atsushi Suzuki
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

6.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 7.  Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

Authors:  Bryan D White; Andy J Chien; David W Dawson
Journal:  Gastroenterology       Date:  2011-12-08       Impact factor: 22.682

8.  Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Authors:  Daniela Sia; Bojan Losic; Agrin Moeini; Laia Cabellos; Ke Hao; Kate Revill; Dennis Bonal; Oriana Miltiadous; Zhongyang Zhang; Yujin Hoshida; Helena Cornella; Mireia Castillo-Martin; Roser Pinyol; Yumi Kasai; Sasan Roayaie; Swan N Thung; Josep Fuster; Myron E Schwartz; Samuel Waxman; Carlos Cordon-Cardo; Eric Schadt; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Nat Commun       Date:  2015-01-22       Impact factor: 14.919

9.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.

Authors:  Yuchen Jiao; Timothy M Pawlik; Robert A Anders; Florin M Selaru; Mirte M Streppel; Donald J Lucas; Noushin Niknafs; Violeta Beleva Guthrie; Anirban Maitra; Pedram Argani; G Johan A Offerhaus; Juan Carlos Roa; Lewis R Roberts; Gregory J Gores; Irinel Popescu; Sorin T Alexandrescu; Simona Dima; Matteo Fassan; Michele Simbolo; Andrea Mafficini; Paola Capelli; Rita T Lawlor; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Filippo de Braud; Aldo Scarpa; William Jarnagin; David Klimstra; Rachel Karchin; Victor E Velculescu; Ralph H Hruban; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Laura D Wood
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

10.  WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Authors:  Luke Boulter; Rachel V Guest; Timothy J Kendall; David H Wilson; Davina Wojtacha; Andrew J Robson; Rachel A Ridgway; Kay Samuel; Nico Van Rooijen; Simon T Barry; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808
View more
  8 in total

Review 1.  Emerging molecular therapeutic targets for cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  J Hepatol       Date:  2017-04-05       Impact factor: 25.083

2.  NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.

Authors:  Shikai Hu; Laura Molina; Junyan Tao; Silvia Liu; Mohammed Hassan; Sucha Singh; Minakshi Poddar; Aaron Bell; Daniela Sia; Michael Oertel; Reben Raeman; Kari Nejak-Bowen; Aatur Singhi; Jianhua Luo; Satdarshan P Monga; Sungjin Ko
Journal:  Gastroenterology       Date:  2022-05-10       Impact factor: 33.883

Review 3.  Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.

Authors:  Guergana G Panayotova; Flavio Paterno; James V Guarrera; Keri E Lunsford
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 4.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

5.  Optimizing the Method of Cell Separation from Bile of Patients with Cholangiocarcinoma for Flow Cytometry.

Authors:  Yafei Xia; Yuan Gao; Botao Wang; Hui Zhang; Qi Zhang
Journal:  Gastroenterol Res Pract       Date:  2019-05-02       Impact factor: 2.260

6.  Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.

Authors:  Benjamin Goeppert; Marcus Renner; Stephan Singer; Thomas Albrecht; Qiangnu Zhang; Arianeb Mehrabi; Anita Pathil; Christoph Springfeld; Bruno Köhler; Christian Rupp; Karl Heinz Weiss; Anja A Kühl; Ruza Arsenic; Ulrich Frank Pape; Arndt Vogel; Peter Schirmacher; Stephanie Roessler; Nalân Utku
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

7.  A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer.

Authors:  Carolina Reduzzi; Marta Vismara; Marco Silvestri; Luigi Celio; Monica Niger; Giorgia Peverelli; Filippo De Braud; Maria G Daidone; Vera Cappelletti
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.396

8.  Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.

Authors:  Mingxun Wang; Ziyan Chen; Pengyi Guo; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2020-12-04       Impact factor: 5.295
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.